Once-Weekly TransCon® CNP (Navepegritide) Receives Positive CHMP Opinion for the Treatment of Achondroplasia in Children
Ascendis Pharma AS ASND
News
Ascendis to Share Latest Advances in Hypoparathyroidism and Achondroplasia Programs at ASBMR 2026
Ascendis Pharma Regains Rights to Weight-Loss Technology; Share Buyback Approved
Ascendis Announces Planned $400 Million Share Repurchase Program
Ascendis to Regain Rights to TransCon® Technology in Metabolic and Cardiovascular Diseases
First Infant Data from Ascendis Trial of Once-Weekly TransCon CNP (Navepegritide) Presented at ESPE 2026
Ascendis Pharma to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
Ascendis to Share Its Latest Endocrinology Rare Disease Data at ESPE 2026
Ascendis and BioMarin Enter Binding Term Sheet for a Global Settlement and License Agreement Related to YUVIWEL® (Navepegritide)
Ascendis Announces Oral Presentation of Week 104 Data from Its Pivotal Trial of TransCon® CNP (Navepegritide) at ISDS 2026
Ascendis Pharma Reports Second Quarter 2026 Financial Results
Ascendis to Report Second Quarter 2026 Financial Results and Provide Business Update on August 13, 2026
Ascendis Announces COACH Week 78 Results and Provides Update on Achondroplasia Programs and YUVIWEL® Uptake in the U.S.
Ascendis Pharma Gets Orphan Drug Exclusivity for Yuviwel
Eight stock picks to play one of the healthiest corners of the market
United States